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Abstract
Objectives:  Although  recognized  for  decades,  little  is  known  about  the  etiology,  physiopathol-
ogy, and  prevention  of  persistent  pulmonary  hypertension  of  the  newborn  (PPHN),  and  its
treatment  remains  a  major  challenge  for  neonatologists.  In  this  review,  the  clinical  features
and  physiopathology  of  the  syndrome  will  be  addressed,  as  well  as  its  general  and  speciﬁc
treatments.
Data  source:  A  review  was  carried  out  in  PubMed,  Cochrane  Library,  and  MRei  consult  databases,
searching for  articles  related  to  the  syndrome  and  published  between  1995  and  2011.
Data synthesis:  Risk  factors  and  the  physiopathological  mechanisms  of  the  syndrome  are  dis-
cussed. The  clinical  presentation  depends  on  the  different  factors  involved.  These  are  related
to  the  etiology  and  physiopathology  of  the  different  forms  of  the  disease.  In  addition  to  the
measures  used  to  allow  for  the  decrease  in  pulmonary  vascular  resistance  after  birth,  in  some
instances  pulmonary  vasodilators  will  be  required.  Although  inhaled  nitric  oxide  has  proved
effective,  other  vasodilators  have  been  recently  used,  but  clinical  evidence  is  still  lacking  to
demonstrate  their  beneﬁts  in  the  treatment  of  PPHN.
Conclusions:  Despite  recent  technological  advances  and  new  physiopathological  knowledge
of this  disease,  mortality  associated  with  PPHN  remains  at  10%.  More  clinical  research  and
evidence-based  experimental  results  are  needed  to  prevent,  treat,  and  reduce  the  morbid-
ity/mortality  associated  with  this  neonatal  syndrome.
©  2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  Este é um artigo Open Access sob a licença de CC BY-NC-ND Please cite this article as: Cabral JE, Belik J. Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology
nd treatment. J Pediatr (Rio J). 2013;89:226--42.
∗ Corresponding author.
E-mail: dr.jcabral@terra.com.br (J.E.B. Cabral).
021-7557      © 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.
ttp://dx.doi.org/10.1016/j.jped.2012.11.009
Este é um artigo Open Access sob a licença de CC BY-NC-ND
Persistent  pulmonary  hypertension  of  the  newborn  227
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Óxido  nítrico
Hipertensão  pulmonar  persistente  neonatal:  recentes  avanc¸os  na  ﬁsiopatologia  e
tratamento
Resumo
Objetivos:  Embora  reconhecida  há  décadas,  ainda  pouco  se  sabe  a  respeito  da  etiologia,  ﬁsiopa-
tologia e  prevenc¸ão  da  hipertensão  pulmonar  persistente  neonatal  (HPPN),  e  seu  tratamento
continua  a  ser  um  grande  desaﬁo  para  os  neonatologistas.  Nesta  revisão,  vamos  abordar  as  car-
acterísticas  clínicas  e  os  mecanismos  ﬁsiopatológicos  da  síndrome,  assim  como  seu  tratamento
geral  e  especíﬁco.
Fontes  de  dados:  Fizemos  uma  revisão  nas  bases  de  dados  PubMed,  Cochrane  Library  e  MRei
Consult, procurando  por  artigos  relacionados  à  síndrome  e  publicados  entre  1995e  2011.
Síntese de  dados: São  discutidos  os  fatores  de  risco  e  os  mecanismos  ﬁsiopatológicos  da  sín-
drome. O  quadro  clínico  depende  dos  diferentes  fatores  envolvidos,  que  provavelmente  estão
relacionados  com  a  etiologia  e  o  mecanismo  ﬁsiopatológico.  Além  das  medidas  utilizadas  para
permitir  a  queda  da  resistência  vascular  pulmonar  após  o  nascimento,  alguns  casos  necessitam
de  vasodilatadores  pulmonares.  Embora  o  óxido  nítrico  tenha  se  provado  efetivo,  recentemente,
outros vasodilatadores  têm  sido  usados,  mas  ainda  faltam  evidências  clínicas  para  comprovar
seus  benefícios  no  tratamento  da  HPPN.
Conclusões:  Apesar  dos  recentes  avanc¸os  tecnológicos  e  dos  novos  conhecimentos  ﬁsiopatológi-
cos, a  mortalidade  associada  à  HPPN  ainda  é  de  10%.  São  necessárias  mais  pesquisas  clínicas  e
resultados  experimentais  baseados  em  evidências  para  prevenir,  tratar  e  reduzir  a  morbimor-
talidade  associada  a  esta  síndrome  neonatal.
©  2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Persistent  pulmonary  hypertension  of  the  newborn  (PPHN)
is a  syndrome  that,  although  recognized  for  over  30  years,
continues to  challenge  physicians,  and  little  is  known  about
its etiology,  pathogenesis,  and  prevention.  With  the  excep-
tion of  inhaled  nitric  oxide  (NO),  treatment  is  limited  and
the use  of  new  drugs  is  based  solely  on  experimental  evi-
dence, or  in  the  treatment  of  adults  with  primary  pulmonary
hypertension.
The clinical  features  of  the  syndrome  and  its  general
and speciﬁc  treatment  were  reviewed  in  the  present  study.
For a  better  understanding  of  its  pathogenesis  and  the  use
of certain  pharmacological  interventions,  an  overview  of
the factors  responsible  for  the  control  of  pulmonary  vascu-
lar tone  and  hemodynamic  alterations  during  the  transition
from fetal  to  postnatal  life  is  necessary.
Treatment  consists  of  general  measures  to  allow  the  phys-
iologic decrease  in  pulmonary  vascular  resistance  after  birth
and the  use  of  speciﬁc  therapies,  when  indicated.  Despite
the common  terminology,  pulmonary  hypertension  of  the
newborn and  primary  pulmonary  hypertension  in  adults  are
quite distinct  diseases.  The  neonatal  form  is  much  more  fre-
quent than  the  adult  disease,  but  it  has  a  better  prognosis
(Table 1).
Pulmonary vascular tone controlThe  control  of  vascular  resistance  to  blood  ﬂow  is  exerted
by the  arterial  musculature.  Contraction  of  this  muscle,
present in  the  arterial  wall  middle  layer,  leads  to  reduc-
tion of  its  lumen,  increased  resistance  to  blood  ﬂow,  and
u
t
o
tonsequent  decreased  distal  perfusion.  Although  both  arter-
es and  veins  contain  smooth  musculature,  the  control  of
lood ﬂow  is  mainly  performed  by  small-caliber  arterioles.
The  pulmonary  circulation  is  completely  distinct  from
he systemic  one.  In  the  postnatal  period,  the  systemic  cir-
ulation exhibits  a  much  higher  vascular  resistance  than
he pulmonary,  and  responds  to  stimuli  such  as  partial  oxy-
en pressure  and  alterations  in  blood  differently  than  the
ulmonary circulation.  Hypoxemia  dilates  the  systemic  cir-
ulation, whereas  the  opposite  is  observed  in  the  pulmonary
rteries. In  this  review  only  the  pulmonary  circulation  will  be
iscussed, but  the  reader  should  keep  in  mind  that  the  phys-
ology of  the  two  circulations  is  largely  distinct,  and  this  fact
as important  clinical  implications,  mainly  regarding  the  use
f  vasoactive  drugs.
The control  of  the  vascular  muscle  is  largely  determined
y factors  produced  by  endothelial  cells.  Production  of  NO,
rostacyclin, and  vascular  endothelial  growth  factor  (VEGF)
y endothelial  cells  leads  to  relaxation,  whereas  endothe-
in, thromboxane,  and  prostaglandin  F2 induce  contraction
f the  pulmonary  vascular  smooth  muscle.  Blood  ﬂow  has  a
irect effect  on  dilation/constriction  of  the  vessel  through
he shear  stress  phenomenon.  NO  is  produced  in  propor-
ion to  this  shear  stress.  Therefore,  the  higher  the  ﬂow,
reater is  the  shear  stress  and  therefore,  the  tissue  per-
usion.
Some blood  factors  also  control  the  pulmonary  ﬂow,
nd oxygen  and  pH  have  the  greatest  clinical  importance.
he location  of  the  oxygen  sensors  in  the  lungs  remains
nclear, but  probably  involves  precapillary  arterioles  close
o the  alveolus.  Thus,  it  is  not  an  increase  in  arterial
xygen pressure  (PaO2)  that  leads  to  pulmonary  vasodila-
ion, but  alveolar  oxygen  tension.  Regarding  the  pH,  the
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Table  1  Comparison  between  adult  and  neonatal  pulmonary  hypertension.
Newborn  Adult
Deﬁnition  Increased  pulmonary  vascular  resistance  and
presence  of  right-left  shunt  at  the  foramen
ovale  and/or  ductus  arteriosus  level
Pulmonary  artery  pressure  >  25  or  30  mmHg
during  exercise  and  ‘‘pulmonary  wedge
pressure’’  <  15  mmHg.
Prevalence
Idiopathic
Familial
1.9/1,000 live  births 2-3/million
0.2-0.3/million
Female:Male  Predominance  of  male  gender  >  2:1
Patient  age  at  onset:  Neonatal  period  36  years
Etiology  Multifactorial  Multifactorial
Genetic  mutations
(BMPR II)
? 75%  familial;  10%  to  40%  idiopathic
Clinical progression  Generally  transient  Chronic  course  with  progressive  worsening
Five-year survival  90%  (15%  to  20%  with  neurological  deﬁcit)  30%  to  40%  (older  children);  50%  (adults)
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pBMPR II, bone morphogenetic protein receptor II.
ulmonary  circulation  responds  with  vasodilation  in  the
resence of  alkalosis  and  vasoconstriction  in  response  to
cidosis.
Fig. 1  shows  the  complexity  of  the  cascade  respon-
ible for  pulmonary  vasodilation  that  depends  on  NO
cyclic GMP)  and  prostacyclin  (cyclic  AMP).  Both  lead  to
timulation of  the  myosin  light  chain  phosphatase,  and
ephosphorylation of  the  latter  leads  to  relaxation  of  the
ascular smooth  muscle.  Conversely,  many  factors  have  an
nhibitory effect  on  the  vasorelaxation  process.  Below  is  a
ummarized description  of  some  of  these  factors  accord-
ng to  their  importance  in  different  clinical  presentations
f this  syndrome  and  the  use  of  drugs  that  act  through  their
odulation.
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igure  1  Factors  responsible  for  pulmonary  vascular  relaxation.
DMA,  asymmetric  dimethylarginine;  EDHF,  endothelial  hyperpolariz
hosphatase;  NOS,  nitric  oxide  synthase;  PGI,  prostacyclin;  PKA,proNO is  synthesized  by  the  vascular  endothelium  from  L-
rginine in  response  to  several  stimuli.1 The  nitric  oxide
ynthase converts  L-arginine  to  L-citrulline,  releasing  NO  in
his reaction.  There  are  three  nitric  oxide  synthase  isoforms.
he endothelial  (eNOS),  present  in  endothelial  cells,  and
he neuronal  (nNOS),  present  in  muscle  cells,  are  respon-
ible for  production  of  NO  under  physiological  conditions,
hereas the  inducible  form  (iNOS)  is  only  activated  during
nﬂammatory processes.
Based on  evidence  from  animal  models,  which  haveemonstrated that  the  expression  of  eNOS  is  maximal  at
irth, an  important  role  has  been  attributed  to  NO  pro-
uced by  this  enzyme  in  pulmonary  vasodilation.2,3 However,
t is  currently  known  that  an  endogenous  inhibitor  of  this
pling
lline Peroxynitrate
Reactive oxygen
EDHF (H2O2?)
P2GI
cAMP
PKA
Rho-Kinase
osin
ing  factor;  H2O2,  hydrogen  peroxide;  MLCP,  myosin  light  chain
tein  kinase  A;  PKG,  protein  kinase  G.
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enzyme,  asymmetric  dimethylarginine  (ADMA)  is  at  much
higher levels  in  the  fetus  and  newborn,  including  humans,
in comparison  to  adults.4 This,  associated  with  the  fact  that
the concentration  of  arginases,  which  are  enzymes  that  com-
pete  with  eNOS  for  the  L-arginine  substrate,  is  increased
during fetal  and  immediate  postnatal  periods,5 calls  into
question the  importance  of  NO  in  the  pulmonary  vasodilation
that occurs  at  birth.
NO stimulates  the  soluble  guanylate  cyclase  (sGC)
enzyme in  pulmonary  vascular  smooth  muscle  cells,  lead-
ing to  the  conversion  of  guanosine  triphosphate  (GTP)
nucleotide into  cyclic  guanosine  monophosphate  (cGMP).
The increase  in  intracellular  cGMP  leads  to  a  decrease  in
calcium inﬂux  and  relaxation  of  smooth  muscle  cells  by  stim-
ulating protein  kinase  G.6,7 Based  on  evidence  obtained  in
animal models,  it  is  considered  that  the  contents  of  pul-
monary sGC  is  higher  in  the  fetus  and  newborn  and  decreases
with age.8--11 The  phosphodiesterase  5  (PG5)  enzyme  present
in the  pulmonary  vasculature  degrades  cGMP,  and  thus
controls the  degree  of  vasodilation.12 Factors  related  to
development have  a  great  importance  in  the  generation  of
cGMP. Pulmonary  hypertension  is  associated  with  increased
PG5 activity,13,14 and  inhibition  of  this  enzyme  with  sildenaﬁl
is currently  one  of  the  pharmacological  interventions  used
in this  disease.15,16
The  prostaglandin  (PG)  system  is  also  involved  in  the
fetal-newborn pulmonary  circulation  transition.  It  causes
vasodilatation through  a  parallel  pathway  that  is  comple-
mentary to  NO,  and  can  thus  potentiate  its  action  (Fig.  1).
Prostaglandins are  synthesized  from  arachidonic  acid,  and
vascular smooth  muscle  cells  activate  the  adenylate  cyclase
enzyme, which  converts  adenosine  triphosphate  (ATP)  into
cyclic adenosine  monophosphate  (cAMP).  An  intracellular
increase of  this  enzyme  also  results  in  relaxation  of  the  vas-
cular smooth  musculature  by  decreasing  the  calcium  inﬂux.
Prostacyclin (PGI2)  is  considered  the  most  potent  in  this
system, although  prostin  (PGE1),  normally  used  to  main-
tain patency  of  the  ductus  arteriosus,  has  also  been  shown
to be  an  effective  pulmonary  vasodilator  in  newborns  with
pulmonary hypertension.17
The  phosphodiesterase  type  III  (PG3)  enzyme  degrades
cAMP and  controls  the  degree  of  vasodilation.18 Endothelin  1
(ET-1) is  a  member  of  the  endothelin  family,  and  its  effect  on
pulmonary vascular  resistance  is  mediated  by  two  receptor
subtypes: ETA  and  ETB.  Both  are  present  in  the  smooth  mus-
cle cell  and  cause  vasoconstriction  and  cell  proliferation.
ETB receptors  are  also  present  in  the  vascular  endothelium,
where they  contribute  to  the  regulation  of  pulmonary  vas-
cular tone  through  the  release  of  NO.  During  fetal  life,  the
maintenance of  high  pulmonary  vascular  tone  is  supported
in part  by  ET-1,  and  its  level  is  elevated  in  animal  models  of
PPHN.19
Several  other  substances  involved  in  the  fetal  circulation
transition are  being  identiﬁed.  Experimental  studies  sug-
gest that  superoxide  radicals,  generated  by  oxidative  stress,
decouple eNOS  (Fig.  1),  and  compete  with  and  inhibit  the
biological action  of  NO  by  generating  peroxynitrite.20 This
molecule, in  addition  to  its  deleterious  effects  on  several
cell functions,  also  has  an  important  vasoconstrictor  effect
in the  newborn  rat.21 Recent  studies  have  demonstrated
that VEGF  releases  NO,  and  induces  pulmonary  vasodilation
by increasing  cGMP  activity.22 Pharmacological  inhibition  of
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EGF  induces  pulmonary  hypertension  in  newborn  and  adult
ats,  showing  the  importance  of  this  factor  in  pulmonary
ascular angiogenesis.23--25 The  intracellular  levels  of  cyclic
GMP are  also  increased  by  natriuretic,  atrial  (ANP),  and
ype B  (BNP)  peptides,  which  stimulate  particulate  guany-
ate cyclase,  an  isoform  of  sGC.7,26,27
Another  molecule  that  plays  an  important  role  in  the
ontrol of  pulmonary  vascular  tone  is  the  rho-kinase.  When
ctivated, this  molecule  has  an  inhibitory  effect  on  the
yosin light  chain  phosphatase,  preventing  the  relaxation
f vascular  smooth  muscle  (Fig.  1).  Rho-kinase  is  increased
n animal  models  of  pulmonary  hypertension  of  the  newborn,
nd its  inhibition  reduces  disease  severity  in  several  animal
odels.28--32
emodynamic alterations during birth
etal  pulmonary  circulation  is  characterized  by  elevated
ulmonary vascular  resistance  and  the  presence  of  right-to-
eft shunting  via  the  ductus  arteriosus  and  foramen  ovale.
hese channels  allow  blood  ﬂow  from  the  right  atrium  to
each the  aorta,  since  only  10%  of  the  cardiac  output  of
he right  ventricle  reaches  the  lungs,  as  a  result  of  high
etal pulmonary  vascular  resistance.33,34 Fig.  2  outlines  the
haracteristics of  fetal  circulation.
Several  mechanisms  contribute  to  the  maintenance
f high  pulmonary  vascular  resistance  in  the  fetal
eriod. The  main  mechanisms  include  low  oxygen  ten-
ion, decreased  production  of  vasodilators  (such  as  NO
nd prostaglandins  with  vasodilator  characteristic  [prosta-
yclin]), and  increased  production  of  vasoconstrictive
rostaglandin  (thromboxane)  and  others  such  as  endothe-
ins.
Minutes after  birth,  the  pulmonary  arterial  pressure
apidly drops  to  50%  of  the  systemic  pressure,  and  pulmonary
lood ﬂow  increases  by  approximately  ten  times  with  the
nset of  respiration.  The  factors  responsible  for  this  sudden
ecrease in  vascular  resistance  after  birth  are  related  to  the
xpansion and  oxygenation  of  the  alveoli,  onset  of  continu-
us respiration,  and  clamping  of  the  umbilical  cord  (Fig.  3).
t is  believed  that  pulmonary  vascular  resistance  depends  on
he association  between  humoral  constricting  and  dilating
actors. During  fetal  life,  constricting  factors  predominate,
hereas dilating  factors  prevail  after  birth.
eﬁnition
PHN  is  a syndrome  characterized  by  the  presence  of  ele-
ated pulmonary  vascular  resistance  and  right-left  shunt
hrough the  ductus  arteriosus  and/or  foramen  ovale.  Con-
rary to  primary  pulmonary  hypertension  in  adults,  the
ewborn syndrome  is  not  deﬁned  by  a  speciﬁc  pressure
f the  pulmonary  circulation  (Table  1).  The  diagnosis  of
PHN is  conﬁrmed  regardless  of  the  pulmonary  arterial  pres-
ure, as  long  as  it  is  accompanied  by  right-left  shunt  and
bsence of  congenital  heart  abnormalities.  This  concept  is
ery important,  as  not  only  the  increase  in  pulmonary  vascu-
ar resistance,  but  also  the  capacity  of  the  right  ventricle  to
vercome this  resistance,  are  determining  factors  in  neona-
al pulmonary  hypertension.
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Figure  2  Fetal  circulation.
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PHN  affects  mainly  at-term  or  post-term  newborns,
lthough also  present  in  premature  infants.35 The  preva-
ence of  PPHN  in  newborns  is  not  well  characterized,  and
s probably  underestimated  due  to  failure  in  its  detection
hen associated  with  parenchymal  pathology.  A  recent
tudy in  12  major  North  American  centers  documented  the
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Figure  3  Pulmonary  vascular  resistance  durirevalence  of  this  syndrome  as  1.9/1,000  in  the  population
f neonates  born  at  term,  with  a  mortality  of  11%.36 In
he UK,  the  incidence  ranged  from  0.4  to  0.68/1,000  live
irths.37 In  comparison  with  these  international  statistics,
etween 2000  and  2005,  Hospital  São  Luiz,  a  service  with
,000 deliveries/year  and  a  high-complexity  neonatal
ntensive care  unit  with  54  beds,  recorded  2  cases/1,000
ive births,  and  mortality  rates  of  11.6%.
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Etiology
The  etiology  of  PPHN  is  considered  to  be  multiple.  Certain
maternal conditions  such  as  obesity,  diabetes,  asthma,  black
or Asian  ethnicity,  and  other  neonatal  factors  such  as  post-
maturity and  neonates  born  large  for  gestational  age  are
associated with  a  higher  incidence  of  PPHN.38
The  condition  most  commonly  associated  with  PPHN  in
the United  States  is  the  meconium  aspiration  syndrome
(42%), followed  by  the  idiopathic  (27%).  Other  conditions
include respiratory  distress  syndrome,  sepsis,  asphyxia,  and
pulmonary hypoplasia  secondary  to  congenital  diaphrag-
matic hernia.39
In  the  Hospital  São  Luiz,  the  prevalence  of  the  idio-
pathic form  was  70%,  much  higher  when  compared  to  U.S.
services.39 This  is  probably  due  to  the  high  incidence  of
cesarean delivery  in  Brazil.  Newborns  delivered  by  cesarean
section with  no  labor  have  a  signiﬁcantly  higher  chance  of
developing PPHN  than  infants  born  to  mothers  with  labor
or with  normal  vaginal  delivery.40 Labor  is  associated  with
the interruption  of  production  and  increased  resorption  of
alveolar ﬂuid,  thus  preventing  respiratory  distress,  char-
acteristic of  the  transient  tachypnea  of  the  newborn.41
Other  conditions  associated  with  PPHN  at  Hospital  São
Luiz included  infection,  meconium  aspiration  syndrome,  and
respiratory distress  syndrome  (Fig.  4).
Among  the  drugs  used  by  the  mother,  the  most  com-
monly associated  with  PPHN  are  anti-inﬂammatory  drugs
and serotonin-reuptake  inhibitors  antidepressants.  The  anti-
inﬂammatory drugs  lead  to  premature  closing  of  the  ductus
arteriosus by  decreasing  the  release  of  prostaglandins,
through the  inhibition  of  cyclooxygenase  enzymes.
In  animal  models,  early  closure  of  the  ductus  arte-
riosus induces  alterations  in  the  pulmonary  vasculature
very similar  to  those  observed  in  newborns  with  PPHN.42,43
Early  closure  of  the  ductus  arteriosus  is  probably  an
uncommon cause  of  pulmonary  hypertension  syndrome.
Fetal echocardiographic  studies  have  shown  that  there  is
indeed a  constrictive  effect  when  inhibitors  cyclooxygenase
inhibitors are  used,  and  that  this  effect  is  increased  when
corticosteroids are  also  administered.44,45 This  constrict-
ing effect  of  cyclooxygenase  inhibitors,  however,  may  is
transient even  in  women  receiving  continuous  treatment.46
50%
20%
20%
5% 5%
Clin perinatol 2004;
31 : 591-611
Meconium Idiopathic Infection RDS Others
70%
20%
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Figure  4  Prevalence  of  comorbidity  associated  with  PPHN
syndrome. Data  for  North  America  refer  to  the  publication  by
Walsh-Sukys et  al., 36 HMSL,  Hospital  e  Maternidade  São  Luiz.
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ore  data  are  needed  to  determine  the  role  of  the  early
losure of  the  ductus  arteriosus  during  pregnancy  in  the
athogenesis of  PPHN.
Recent studies  have  demonstrated  an  association
etween antidepressants  used  by  mothers  in  the  third
rimester of  pregnancy  and  PPHN  syndrome.47--49 The  preva-
ence in  newborns  exposed  during  fetal  life  to  selective
erotonin-reuptake  inhibitors  is  four  fold  increased.  In
regnant rats,  administration  of  ﬂuoxetine  induces  pul-
onary vascular  changes  in  the  fetus,  comparable  to  those
bserved in  human  infants  with  PPHN.50 Recently,  however,
t least  one  study  involving  1,104  infants  born  to  moth-
rs who  received  antidepressants  in  the  third  trimester
nd an  equal  number  of  controls  failed  to  demonstrate
his association.51 More  research  in  this  area  is  needed  to
larify whether  there  is  an  association  between  PPHN  and
xposure during  fetal  life  to  selective  serotonin-reuptake
nhibitors.
hysiopathology
onsidering  that  PPHN  is  a  syndrome  secondary  to  increased
ulmonary vascular  resistance,  to  the  point  of  inducing
ight-left shunt,  its  physiopathology  is  related  to  the  major
actors that  lead  to  these  alterations  during  the  peri-
atal period.  The  following  classiﬁcation  illustrates  the
ifferent categories  of  diseases  associated  with  increased
ulmonary vascular  resistance.  A  disease  classiﬁed  in  one
ategory often  has  manifestations  characteristics  of  another
orm. Fig.  5  illustrates  some  of  the  forms  described
elow.
asoconstriction
his  category  includes  pathologies  where  the  number  of
essels, the  pulmonary  structure,  and  the  pulmonary  vas-
ular branching  are  normal,  but  the  smooth  musculature  of
essels responsible  for  the  resistance  to  blood  ﬂow  is  con-
tricted (Fig.  5A).  These  pathologies  show  disequilibrium  in
he balance  of  vasoactive  substances,  with  a predominance
f vasoconstrictor  substances  over  vasodilators.  This  cat-
gory is  usually  associated  with  diseases  or  conditions  of
cute characteristics,  such  as  perinatal  asphyxia,  sepsis,  or
etabolic acidosis.  As  they  are  associated  to  vasoconstric-
ion, pathologies  related  to  this  form  of  PPHN  are  amenable
o treatment  with  vasodilators.
ulmonary  vascular  remodeling
iseases  classiﬁed  in  this  category  exhibit  typical  histo-
ogical characteristics,  with  an  increased  layer  of  arterial
ascular smooth  muscle  and  its  extension  to  intra-acinar
rteries, which  are  not  usually  muscularized  (Fig.  5B).
vidence obtained  from  animal  models  with  pulmonary
ypertension indicates  that  excessive  musculature  of  the
ascular wall  has  an  important  role  in  vasoconstriction.
he increase  in  pulmonary  vascular  resistance  in  these
athologies is  associated  with  the  alterations  caused  by  this
eometric remodeling  that  leads  to  the  closing  of  the  lumen,
mpairing blood  ﬂow.
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pigure  5  Pathogenesis  of  PPHN  syndrome:  vasoconstriction  (A
The  pathogenesis  of  these  conditions  involves  stimula-
ion of  a  number  of  factors  that  regulate  smooth  muscle
roliferation and  extracellular  matrix  deposition.  These  dis-
ases have  a  chronic  characteristic,  which  develops  during
etal life  as  in  cases  of  placental  dysfunction  associated  with
hronic fetal  hypoxemia,  premature  closure  of  the  ductus
rteriosus, or  exposure  to  drugs  during  the  fetal  period.  This
athological manifestation  may  also  be  present  in  infants
ho develop  PPHN  only  after  birth.  It  is  believed  that  in
hese cases,  the  maintenance  of  pulmonary  vasoconstriction
ith an  increase  in  pulmonary  artery  pressure  for  a  pro-
onged period  of  time  leads  to  vascular  remodeling.52 The
esponse to  vasodilators  in  neonates  with  pulmonary  vascu-
ar remodeling  is  limited  or  absent,  and  mortality  is  high.
ulmonary  vascular  hypoplasia
he  growth  and  development  of  the  pulmonary  vascula-
ure depend  on  an  actual  process  of  generating  new  blood
essels (vasculogenesis)  and  their  progressive  branching
angiogenesis) to  allow  adequate  gas  exchange  in  lung  level
Fig. 5C).
Diseases classiﬁed  in  this  category  present  signiﬁcant
lterations in  vasculogenesis  or  angiogenesis,  resulting  in
ypoplasia of  the  pulmonary  vascular  bed.  The  increase  in
ulmonary vascular  resistance  in  these  diseases  is  related
o the  incapacity  of  the  pulmonary  vasculature  to  accom-
odate right  ventricular  cardiac  output.  The  alterations  in
aCO2 and  PaO2 observed  in  these  diseases  are  secondary,
v
a
s
cscular  remodeling  (B),  angiogenesis,  and  vasculogenesis  (C).
ot  only  to  the  right-left  shunt,  but  also  to  inadequate
erfusion of  the  lung.  Examples  include  congenital  diaphrag-
atic hernia  and  pulmonary  hypoplasia  secondary  to  early
nd prolonged  oligohydramnios.
Data obtained  from  animal  models  of  congenital  unilat-
ral diaphragmatic  hernia  demonstrate  that  not  only  there
s vascular  hypoplasia  in  the  lung  affected  by  the  hernia,
ut also  that  there  is  evidence  of  vascular  remodeling  in
he other  lung.53,54 Minimal  or  absent  response  to  vasodila-
ors is  usually  observed  in  diseases  of  this  category,  and  the
rognosis is  guarded.
bstruction
he  lung  in  this  category  presents  a  normal  number  and
tructure of  vessels.  However,  there  is  pulmonary  blood  ﬂow
estriction caused  by  alterations  in  blood  viscosity  (poly-
ythemia) or  by  anomalous  pulmonary  venous  drainage.
ulmonary  parenchymal  pathology
he  hypoxic  pulmonary  vasoconstriction  response  ensures
n optimum  balance  between  alveolar  ventilation  and  per-
usion, by  reducing  blood  ﬂow  to  unventilated  units.  This
hysiological behavior  has  an  important  effect  on  pulmonary
ascular resistance.  Diseases  associated  with  decreased
lveolar ventilation  (such  as  pneumonia,  aspiration,  and
urfactant deﬁciency)  lead  to  an  increase  in  pulmonary  vas-
ular  resistance  to  prevent  the  perfusion  of  alveolar  units
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affected  by  these  diseases.  To  maintain  gas  exchange,  the
resistance of  the  vasculature  involved  in  alveolar  ventilation
decreases. If  the  pulmonary  process  involves  a  small  per-
centage of  the  lung,  the  pulmonary  vascular  resistance  is  not
altered.  However,  in  the  presence  of  extensive  pulmonary
disease, vascular  resistance  increases  to  the  point  of  induc-
ing right-left  shunt.
Diseases  in  this  category  are  erroneously  classiﬁed  as
associated with  PPHN  syndrome.  The  primary  process,  how-
ever,  is  the  abnormal  alveolar  ventilation,  with  appropriate
vasoconstrictor response  of  the  pulmonary  circulation.
Congenital  deﬁciency  of  surfactant  protein  B  is  an  exam-
ple of  a  condition  that  resembles  PPHN,  however  clearly
distinct.55 Lastly,  certain  congenital  vascular  conditions,
such as  capillary  alveolar  dysplasia,  in  which  the  presence
of pulmonary  hypertension  has  been  reported,56,57 are  also
best placed  into  this  category.  This  congenital  disease,
where there  is  a  misalignment  and  a  drifting  apart  between
the alveolus  and  its  capillaries,  is  probably  associated
with hypoxic  pulmonary  vasoconstriction  and  vascular
hypoplasia.
In theory,  pulmonary  parenchymal  diseases  associated
with pulmonary  hypertension  and  shunt  should  not  be  clas-
siﬁed as  PPHN.  However,  from  a  practical  viewpoint,  it  is
difﬁcult to  separate  this  category  from  the  others.  The  treat-
ment of  diseases  in  this  category  should  be  aimed  at  the
primary lung  condition  and  not  at  pulmonary  vasodilation,
as vasoconstriction  in  these  cases  has  a  protective  effect
on the  ventilation/perfusion  ratio.  Data  from  animal  models
have shown  that  the  use  of  a  vasodilator  (sildenaﬁl)  in  the
presence of  pulmonary  lobar  atelectasis  leads  to  worsening
in oxygenation,  by  interfering  with  the  physiological  hypoxic
pulmonary vasoconstriction  response.58
Iatrogenic  factors
A  commonly  overlooked  factor  responsible  for  the  increase
in pulmonary  vascular  resistance  is  the  use  of  high  mean
pressures during  mechanical  ventilation.  Depending  on  lung
compliance, part  of  the  pressure  used  in  mechanical  venti-
lation can  be  transmitted  to  the  lung  vasculature.  Failure  to
reduce the  pressure  used  to  ventilate  infants  with  clinical
and lung  compliance  improvements  can  lead  to  pulmonary
hypertension. This  occurs  more  often  in  infants  ventilated
with high  frequency  modes,  as  compared  with  conventional
ventilation. Reducing  the  ventilaion  mean  airway  pressure
results in  decreased  pulmonary  vascular  resistance  and  abo-
lition of  the  right-to-left  shunting  in  some  infants.
Right  ventricular  myocardial  dysfunction
As  discussed  above,  PPHN  is  characterized  by  right-to-left
shunt and  not  by  a  speciﬁc  pulmonary  artery  pressure.  This
leads to  the  possibility  of  a  shunt  at  the  level  of  the  foramen
ovale in  clinical  conditions  where  the  pulmonary  vascular
resistance is  not  very  high,  but  right  ventricular  contractil-
ity is  abnormal,  resulting  in  a  higher  right,  as  compared  with
left atrial  pressure.  This  was  demonstrated  in  newborn  pigs,
where constriction  of  the  main  pulmonary  artery  to  the  point
of inducing  right  ventricular  failure  leads  to  right-to-left
shunt at  the  foramen  ovale.59 In  these  conditions,  therapies
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irected  to  enhancing  the  contractility  of  the  right  ventri-
le lead  to  improved  oxygenation  (shunt  reduction),  even
hough the  pulmonary  vascular  resistance  remains  high.
linical features and diagnosis
he  diagnosis  of  PPHN  should  be  suspected  when  the  level  of
ypoxemia is  disproportionate  to  the  degree  of  respiratory
istress and  pulmonary  parenchymal  radiological  ﬁndings.
nfants with  PPHN  exhibit  oxygenation  lability  and  progres-
ive cyanosis  in  the  ﬁrst  hours  of  life.
Cardiac  auscultation  shows  increased  intensity  of  the  sec-
nd heart  sound  due  to  pulmonary  artery  hypertension  and
ystolic murmur  of  the  tricuspid  regurgitation.
Echocardiography  with  Doppler  ﬂow  should  always  be
erformed upon  suspicion  of  PPHN.  It  is  a noninvasive
ethod that  not  only  allows  the  physician  to  assess  the  pres-
nce of  shunt  at  the  ductus  arteriosus  and  foramen  ovale
evel, but  also  conﬁrms  the  absence  of  congenital  heart  dis-
ase and  aids  in  the  evaluation  of  myocardial  contractility.
Echocardiography  provides  an  estimate  of  pulmonary
rtery pressure  by  determining  the  peak  velocity  of  tricus-
id regurgitation,  and  the  pulmonary  vascular  resistance
hrough by  measuring  the  ratio  of  pulmonary  artery  acceler-
tion time  (ACT),  and  right  ventricular  ejection  time  (RVET).
he lower  this  ratio  (ACT/RVET),  the  higher  the  pulmonary
ascular resistance.  In  the  absence  of  tricuspid  regurgita-
ion, which  occurs  in  30%  of  cases,  another  parameter  that
an be  used  to  estimate  pulmonary  artery  pressure  is  the
easurement of  pulmonary  artery  ﬂow,  estimated  by  the
elocity-time integral  of  the  pulmonary  artery  (pulmonary
TI).60 Fig.  6  illustrates  right  ventricular  hypertrophy  in  an
nimal model  of  PPHN  induced  in  fetal  rat  after  pharmaco-
ogical closure  of  the  ductus  arteriosus.61
The  right-to-left  shunt,  typical  of  the  disease  when
t occurs  exclusively  through  the  ductus  arteriosus  (50%
f cases)  can  be  demonstrated  by  the  difference  in  pre-
nd post-ductal  oxygenation.  A  PaO2 difference  >  20  mmHg
etween the  right  radial  artery  (pre-ductal)  and  the  umbili-
al artery  is  considered  indicative  of  a  right-to-left  shunt  at
he ductus  arteriosus  level.  The  same  measurement  can  be
btained noninvasively  through  the  comparative  assessment
f pulse  oximetry  between  pre-  (upper  right  limb)  and  post-
uctal areas  (lower  extremities).  A  difference  >  5%  is  also
ndicative of  shunting.  It  is  important  to  remember  that  the
bsence of  a  difference  in  pre-  and  post-  ductal  oxygenation
nly indicates  that  there  is  no  right-to-left  shunt  at  the  duc-
us arteriosus.  The  presence  of  a  shunt  at  the  foramen  ovale
s only  diagnosed  by  echocardiography.  Fig.  7 shows  the  dif-
erent scenarios  illustrating  that  not  only  the  presence  of
he shunt,  but  also  the  capacity  of  the  right  ventricle  to
vercome the  increased  vascular  resistance,  determines  the
resence and  severity  of  disease.
reatment
eneral  careaintenance  of  a  normal  body  temperature  and  correc-
ion of  electrolyte  and  metabolic  disturbances  are  essential.
ypoxemia, hypercapnia,  and  metabolic  acidosis  lead  to
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Figure  6  Right  ventricle  (RV)  wall  hypertrophy  in  rat  fetuses  exposed  to  indomethacin,  compared  with  normal  rats.  Data  from  a
previously  published  study.61Forame oval
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vPersistent  pulmonary  hypertension  of  the  newborn  
pulmonary  vasoconstriction  and  should  be  promptly  cor-
rected.
In addition  to  general  care,  the  treatment  strategy  is
to maintain  systemic  blood  pressure  at  appropriate  lev-
els, decrease  pulmonary  vascular  resistance,  ensure  oxygen
release to  tissues,  and  minimize  lesions  induced  by  oxygen
and ventilation.
In the  presence  of  parenchymal  lung  disease,  ventila-
tory assistance  should  have  as  strategy  the  improvement
of alveolar  recruitment,  always  preventing  excessive  lung
inﬂation. When  indicated  (hyaline  membrane  disease,  blood
or meconium  aspiration),  the  use  of  surfactant  is  of
great therapeutic  value.  Continuous  heart,  blood  pres-
sure, and  oxygen  saturation  monitoring,  preferably  pre-  and
post-ductal, are  essential.  Children  with  PPHN  are
extremely labile  and  unstable.  Thus,  manipulation  should
be minimal.
Sedatives have  signiﬁcant  side  effects,  and  the  use  of
narcotics such  as  morphine  commonly  leads  to  hypotension.
Sedation, although  necessary,  should  be  maintain  at  the  low-
est possible  level  and  withdrawn  as  soon  as  there  is  clinical
improvement. Muscle  relaxants  should  be  reserved  only  for
newborns in  whom  there  is  great  difﬁculty  establishing  ade-
quate ventilation,  and  unresponsive  to  sedation.
Hemodynamic  support
Myocardial  activity  is  commonly  compromised  in  this  dis-
ease, leading  not  only  to  a  worsening  in  the  right-to-left
shunt at  the  foramen  ovale  (right  ventricular  dysfunction),
but also  to  a  decrease  in  the  cardiac  output  due  to  left  ven-
tricular impairment.  The  use  of  inotropic  agents  is  generally
indicated.62
It  is  worth  mentioning  that  the  use  of  quick  corrections
with colloid  or  crystalloid  solutions,  unless  there  is  evi-
dence of  intravascular  depletion,  is  contraindicated,  since
the right  atrial  pressure  is  usually  high  (increased  pulmonary
vascular resistance  and  right  ventricular  dysfunction).
Excessive administration  of  ﬂuids  in  these  circumstances
results in  further  increase  in  right  atrial  pressure  and  exac-
erbation of  right-to-left  shunt  at  the  foramen  ovale  and
hypoxemia.
Inotropic and  vasopressor  agents  should  be  introduced
early in  an  attempt  to  optimize  cardiac  function,  stabi-
lize systemic  blood  pressure,  and  reduce  extrapulmonary
shunt. Each  of  these  drugs  has  a  distinct  effect  that  should
be taken  into  account  when  choosing  a  speciﬁc  therapy
for each  newborn  (Table  2),  and  all  of  them  have  a  sig-
niﬁcant inotropic  effect.  Dopamine,  through  its  adrenergic
effect, is  the  most  effective  in  increasing  blood  pressure
and therefore  the  most  frequently  used.  However,  there
is some  concern  regarding  a  possible  pulmonary  vasocon-
strictor effect  when  used  at  high  doses.  Dobutamine  has  an
effect of  reducing  left  ventricular  overload,  which  together
with its  inotropic  characteristics  contribute  to  an  increased
cardiac output.  Choosing  the  ideal  vasopressor  for  the  treat-
ment of  newborns  with  hypotension  remains  a  subject  of
great debate.63--65 Attention  to  the  cause  of  hypotension
and myocardial  performance  is  of  great  help  in  therapeutic
decision-making.
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Epinephrine,  in  spite  of  being  the  drug  with  greatest
notropic effect,  also  has  an  adrenergic  vasoconstriction
ffect in  systemic  and  pulmonary  circulation,  which  some-
imes leads  to  a  signiﬁcant  reduction  in  peripheral  and
ulmonary blood  ﬂow.  Recently,  a  study  showed  that  norepi-
ephrine improved  oxygenation  and  decreased  pulmonary
ascular resistance  in  newborns  with  PPHN  through  an
nknown mechanism.66 In  sheep,  norepinephrine  decreases
ulmonary vascular  tone  and  increases  blood  ﬂow  by  acti-
ating alpha-receptors  and  NO  release.67,68
ulmonary vasodilatation
n  response  to  many  vasoactive  drugs,  the  pulmonary  circu-
ation has  a  similar  behavior  to  that  of  systemic  circulation.
hus, the  great  difﬁculty  in  the  pharmacological  treatment
f PPHN  is  to  dilate  the  pulmonary  vessels  without  causing
ystemic. As  the  pulmonary  circulation  shows  vasodilation
ith pH  elevation,  hyperventilation  and  alkalization  have
een widely  used  for  the  treatment  of  this  disease  in
he past.69,70 Hyperventilation  is  no  longer  used  due  to  a
igniﬁcant reduction  in  cerebral  perfusion  when  PaCO2 is
aintained <  25  mmHg,  and  pulmonary  trauma.  Alkalization,
n turn,  when  appropriately  used,  has  beneﬁcial  therapeutic
ffect with  minimal  side  effects.
nhaled NO
his  method  is  currently  considered  the  standard  treatment.
When  administered  by  inhalation  (iNO),  it  reaches  the
lveolar space  and  diffuses  into  vascular  smooth  mus-
le of  the  adjacent  pulmonary  arteries,  where  it  causes
asodilation by  increasing  cGMP  levels.  iNO  continues  to  dis-
eminate, and  in  the  pulmonary  artery  lumen,  it  is  rapidly
ound to  hemoglobin,  restricting  its  effect  on  the  pulmonary
irculation, without  any  effect  on  the  systemic  circulation
Fig. 8).  iNO  is  preferably  distributed  to  the  ventilated  seg-
ents of  the  lungs,  with  increased  perfusion  in  those  areas.
his results  in  an  improved  ventilation/perfusion  ratio,
ecreasing intra-alveolar  shunting  and  improving  oxygen-
tion. When  the  response  is  positive,  improved  oxygenation
s evident  within  a  few  minutes.
Since  1997,  several  clinical  trials  have  demonstrated  a
igniﬁcant improvement  in  oxygenation,  decreased  need
or extracorporeal  membrane  oxygenation  (ECMO)  and/or
educed mortality  in  neonates  older  than  34  weeks  with
evere respiratory  failure.71 Clinical  improvement  in  infants
ith PPHN  occurs  in  approximately  70%  of  patients,  and  the
est results  are  observed  in  the  idiopathic  type.72
In  the  past,  treatment  with  iNO  was  initiated  at  rather
ate stages  of  the  disease,  usually  when  the  oxygenation
ndex was  >  25.  Such  late  intervention  resulted  the  mean
ncidence of  ECMO  and/or  mortality  was  still  40%.  An  earlier
ntroduction of  iNO  is  currently  recommended,  before  pro-
onged exposure  to  high  concentrations  of  oxygen  and  high
entilatory occurs  parameters.
Currently,  the  initial  recommended  concentration  of  iNO
s 20  ppm.  Higher  concentrations  are  not  more  effective,  and
re associated  with  a  higher  incidence  of  methemoglobine-
ia and  formation  of  nitrogen  dioxide.73 Some  studies  have
hown that  concentrations  of  up  to  5  ppm  are  effective  in
236
 
Cabral
 JEB,
 Belik
 J
Table  2  Inotropic  and  vasopressor  drugs  commonly  used  in  pulmonary  hypertension.
Drugs/Dose  Action  mechanism  Effects  Side  effects
Dopamine
2.5  -  20  mcg/kg/min
Endogenous  precursor  of
norepinephrine
Dose-dependent action
2.5 -  5  mcg/kg/min:
Stimulation  of  dopaminergic
receptors
5 -  10  mcg/kg/min:  1
receptors  stimulation
10 -  20  mcg/kg/min:  
receptors  stimulation
Dopa:  mesenteric,  kidney,  brain,  and
spleen  vasodilation
Beta: increase  in  myocardial
contractility and  coronary  ﬂow,  with
increase  in  blood  pressure  and  cardiac
output
Alpha:  peripheral  vasoconstriction  and
increased  systemic  vascular  resistance,
systemic  arterial  pressure,  and
pulmonary  pressure;  decreased  kidney
and  mesenteric  ﬂow
High  doses  increase
pulmonary and  systemic
vascular resistance
Dobutamine
5 -  20  mcg/kg/min
Dopamine  synthetic  analogue.
Stimulates   receptors,  mainly
1, and  has  little  action  over
2
Improves  cardiac  output  through  1
inotropic  action
Little peripheral  vascular  effect
Tachycardia  at  high
doses
Epinephrine
0.05 -  2  mcg/kg/min
Endogenous  catecholamine
with   and    adrenergic  effect,
depending  on  the  dose  0.05  --
0.5 mcg/kg/min:    receptor
stimulation  (1>    2)
0.5  -  2  mcg/kg/min:
stimulation  of    receptors
Improves  cardiac  output  through  potent
inotropic  action
Increases systemic  blood  pressure
Pulmonary  and  systemic
vasoconstriction  at  high
doses
Norepinephrine
0,5 -  2  mcg/kg/min
Endogenous  catecholamine,
which stimulates  1  and  2
receptors, as  well  as  1  and  2
receptors
Improves  cardiac  output  through  the
inotropic  action  of    receptors,  and
increases  blood  pressure  by  peripheral
action  of    receptors
Possible improvement  in  pulmonary
blood  ﬂow  secondary  to  the  release  of
endothelial  nitric  oxide
Systemic and  pulmonary
vasoconstrictor
Milrinone
0.3 -  0.8  mcg/kg/min
Inhibitor  of  phosphodiesterase
enzyme type  III,  which
degrades cAMP
Improves  cardiac  output  by  reducing
afterload
Pulmonary  vasodilation  by  increasing
intracellular  cAMP
Possible systemic
vasodilation  at  high
doses
cAMP, cyclic adenosine monophosphate.
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often leads  to  hypotension,  as  it  is  not  a  selective  pul-Figure  8  Inhaled  NO  and  its  binding  to  hemoglobin.  Hb,
hemoglobin; NO,  nitricoxide.
improving  oxygenation;74,75 lower  concentrations  (2  ppm),  in
addition to  not  being  effective,  reduce  the  response  to  the
subsequent increase  in  concentration  to  20  ppm.76
Once  iniated,  iNO  should  be  gradually  decreased
(decrease of  5  ppm/h  to  5  ppm)  and  withdrawn  after
m
f
h
Table  3  Pulmonary  vasodilator  agents.
Drugs  Administration  dose  Action  mechanism  
Nitric  oxide  Inhaled
5-20  ppm
Produced  in  the  vasc
endothelium, causes
through the  increase
cGMP in  the  lung  sm
Prostaglandins  Prostacyclins
Continuous  IV  or  inhaled
administration
Iloprost: inhaled  -
0.5--2 mcg/kg/dose
Produced  from  arach
cause  vasodilatation
intracellular cAMP  in
muscle
Sildenaﬁl IV  or  oral  route
0.5 --  2  mg/kg/dose  6/6h
Inhibitor of  phosphod
enzyme type  V,  respo
degradation
Milrinone IV  administration
0.3--0.8  mcg/kg/m
Inhibitor  of  the  phos
enzyme type  III,  resp
degradation  of  cAMP
Bosentan  OralDose:  not  established  Non-speciﬁc  antagon
endothelin  receptors
cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monop237
 ppm/4  h.  Such  slow  weaning  is  geared  at  preventing  the
henomenon of  rebound  vasoconstriction,  which  may  be
elated to  the  decreased  endogenous  production  of  NO.
During  the  use  of  inhaled  NO,  continuous  monitoring  of
itrogen dioxide  (generated  by  the  reaction  of  NO  with  oxy-
en) and  daily  serum  levels  of  methemoglobin  should  be
btained. The  methemoglobin  level  must  be  kept  below
%. Inhibition  of  platelet  aggregation  has  been  reported  in
umans; however,  the  occurrence  of  this  side  effect  remains
ontroversial.77,78 Until  this  fact  is  clariﬁed,  the  use  of  iNO
s not  recommend  in  the  presence  of  signiﬁcant  intracranial
leeding.
ulmonary vasodilators
esides  NO,  there  are  no  other  drugs  with  speciﬁc  vasodila-
or effects  for  the  pulmonary  circulation.  Several  drugs,
owever, have  a  predominant  vasodilator  effect  in  PPHN;
hey are  discussed  below  and  are  summarized  in  Table  3.
rostaglandins
rostacyclin  is  the  most  potent  vasodilator  among
rostaglandins. Its  intravenous  use  has  been  long-
stablished in  the  treatment  in  adults  with  pulmonary
ypertension. Most  studies  in  infants  have  shown  a  similar
r greater  effect  when  compared  to  iNO  in  decreasing
ulmonary artery  pressure  and  improving  oxygenation.79,80
ts  use,  however,  requires  a  permanent  vascular  access  andonary vasodilator.  Its  administration  via  inhalation  allows
or selective  pulmonary  vasodilation,  but  with  very  short
alf-life, which  makes  its  administration  difﬁcult.81 Iloprost
Use  in  PPHN
ular
 vasodilation
 in  intracellular
ooth  muscle
Selective pulmonary  vasodilator  is  the
standard  treatment
Monitor methemoglobin  and  NO2 during
use
idonic  acid,  they
 by  increasing
 lung  smooth
Vasodilatation  through  alternative  and
complementary  pathway  to  nitric  oxide;
may  enhance  its  action
Prostacyclin is  a  nonspeciﬁc  pulmonary
vasodilator  and  may  have  systemic
effects
iesterase
nsible  for  cGMP
It  may  potentiate  nitric  oxide
Safe and  easy  to  administer
It may  worsen  oxygenation  due  to
vasodilation  of  unventilated  areas
phodiesterase
onsible  for
May potentiate  the  action  of
prostaglandins
Improves  right  cardiac  output  by
reduction of  afterload
ist  A  and  B Very  seldom  used  in  newborns
hosphate IV, intravenous; NO2, nitrogen dioxide.
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s  a  longer-acting  prostacyclin  analogue  with  speciﬁc  effect
n pulmonary  circulation.82
Some  studies  have  shown  its  effectiveness,  even  in  cases
efractory to  NO.83,84 It  can  be  used  in  the  inhaled  form  in
ntubated patients  or  in  the  nebulized  form  in  spontaneously
reathing patients.85
hosphodiesterase  inhibitors
here  are  11  isoforms  of  phosphodiesterases  (PDEs).  The
ost important  are  the  PDE3  and  PDE5,  which  preferentially
egrade cAMP  and  cGMP,  respectively.
Sildenaﬁl  produces  vasodilation  by  inhibiting  PDE5.
ipyridamole, zaprinast,  and  pentoxifylline  are  PDE5
nhibitors that  are  seldom  used,  as  they  have  important
ystemic effects.
Studies  in  neonates  with  pulmonary  hypertension  have
hown that  sildenaﬁl  selectively  reduces  pulmonary  vascu-
ar resistance  with  few  systemic  effects.86--89 Its  effect  on
ulmonary vasculature  appears  to  be  independent  from  the
nderlying cause,  and  thus  effective  in  idiopathic  pulmonary
ypertension associated  with  heart  conditions,  lung  disease,
nd PPHN.90 In  the  postoperative  period  of  heart  disease,  sil-
enaﬁl decreased  pulmonary  artery  pressure  and  prevented
ebound after  withdrawal  of  NO.91
In  a  Cochrane  meta-analysis  with  37  newborns  from
enters that  lacked  NO  and  high  frequency  ventilation,  sig-
iﬁcant improvement  in  oxygenation  was  observed  in  the
roup receiving  sildenaﬁl.92
Sildenaﬁl  is  safe,  effective,  and  easily  administered.
s discussed  earlier,  its  vasodilator  effect  extends  to
oorly ventilated  areas  in  the  lungs,  which  changes  the
entilation/perfusion ratio,  increases  the  intrapulmonary
hunt, and  worsens  oxygenation.  In  an  animal  model  of
eonatal lobar  atelectasis,  sildenaﬁl  inhibited  pulmonary
asoconstriction in  response  to  hypoxia  and  worsened
xygenation.58 Using  tadalaﬁl,  another  PDE5  inhibitor  in  the
ame animal  model  without  lobar  atelectasis,  a  decrease
n pulmonary  vascular  resistance  and  improved  oxygenation
ere demonstrated.93
Milrinone  causes  pulmonary  vasodilation  by  inhibiting
DE3. Originally  used  to  reduce  the  afterload  and  as  an
notropic agent,  it  also  has  been  shown  to  be  effective  in  the
reatment of  neonatal  pulmonary  hypertension.  Recently,
akshminrusimha et  al.  demonstrated,  in  an  animal  model
f PPHN,  that  pretreatment  with  milrinone  increased  the
ffect of  prostaglandin  in  pulmonary  artery  relaxation.94
his  would  explain  the  ﬁndings  of  Bassller  and  MacNamara,
ho, when  studying  four  and  nine  newborns,  respectively,
emonstrated a  signiﬁcant  improvement  in  oxygenation
ith the  use  of  milrinone  after  unsatisfactory  response  to
NO.95,96
ndothelin  blockers
n  adults,  the  use  of  bosentan,  a  nonspeciﬁc  antagonist
f receptors  A  and  B,  signiﬁcantly  improves  symptoms  and
xercise capacity  in  patients  with  pulmonary  hypertension.
n newborns,  the  plasma  levels  of  ET1  are  high,  with  a  linear
orrelation with  disease  severity.97 These  data  have  stim-
lated the  use  and  publication  of  some  case  reports  with
p
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he  use  of  bosentan  in  neonates  with  PPHN.98,99 The  useful-
ess of  these  agents  in  the  treatment  of  PPHN  still  requires
urther clinical  investigation  before  it  can  be  recommended.
ther  drugs
ther  drugs  have  been  tested  in  animal  models  with
romising effects.  Rho-kinase  is  a protein  that  prevents
asodilatation by  inhibiting  the  dephosphorylation  of  myosin
n smooth  muscle  cells.  Fasudil  and  Y-27632,  rho-kinase
nhibitors, cause  potent  vasodilation  in  experimental  models
f PPHN.29,32 These  studies  suggest  that  rho-kinase  inhibitors
ay play  an  important  role  in  the  treatment  of  PPHN.
Superoxide  dismutase  removes  superoxide  radicals  from
irculation, generated  by  oxidative  stress,  leading  to  pul-
onary vasoconstriction  by  binding  and  competing  with  NO.
n animals,  administration  of  superoxide  dismutase  reduces
ulmonary artery  pressure  and  improves  the  response  to
O.100
The  adenosine  nucleotide  and  its  trinucleotide  ATP  are
otent selective  pulmonary  vasodilators,  through  intracel-
ular increase  of  AMP.  Intravenous  infusion  of  adenosine  in
nfants with  PPHN  syndrome  has  shown  a  signiﬁcant  improve-
ent in  oxygenation.101--103
Magnesium  sulphate  has  been  described  in  some  case
eports.104 However,  the  Cochrane  meta-analysis  did  not
how enough  evidence  to  recommend  the  use  of  this  drug
n PPHN.105
echanical  ventilation  and  surfactant
echanical  ventilation  facilitates  alveolar  recruitment  and
mproves ventilation/perfusion  and  oxygenation.
It  is  still  debatable  whether  high-frequency  ventilation  is
uperior to  conventional  ventilation  in  newborns  with  PPHN.
ome studies  have  shown  that  high-frequency  ventilation
mproves the  efﬁcacy  of  inhaled  NO  in  infants  with  parenchy-
al lung  disease.106
Certain  causes  of  PPHN,  such  as  meconium  aspiration
yndrome and  diaphragmatic  hernia,  are  associated  with
urfactant deﬁciency  or  reduced  activity,107 and  its  use
n neonates  born  to  term  with  severe  respiratory  failure
ecreases the  need  for  ECMO.108
revention
espite  recent  advances,  mortality  associated  with  this  syn-
rome remains  at  10%.  Due  to  the  limited  knowledge  of
ts etiology  and  pathogenesis,  little  is  progress  has  been
ade regarding  prevention.  Based  on  data  from  Hospital
ão Luiz,  70%  of  cases  of  PPHN  are  idiopathic.  Considering
hat elective  C-sections  without  labor  are  associated  with
ost of  these  cases,  attention  regarding  this  practice  and
roper monitoring  of  these  infants  may  play  an  important
reventive role.  Much  has  been  achieved  in  the  diagnosis
nd treatment  of  PPHN  in  the  last  30  years,  but  more  studies
re necessary  to  adequately  prevent  or  avoid  this  syndrome.
Persistent  pulmonary  hypertension  of  the  newborn  
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